ICCS e-Newsletter CSI Winter 2013

Slides:



Advertisements
Similar presentations
CP Unknown Heme-10/19/2011 Kumaran Mudaliar and Girish Venkataraman
Advertisements

Case Study #7 MICR 410 – Hematology Spring 2010 Erik Bayona, Rosa E. Loyola, Lien Pham.
TA OGUNLESI (FWACP)1 CHILDHOOD LEUKAEMIA. TA OGUNLESI (FWACP)2 LEUKAEMIA Heterogenous group of malignant disorders Characterised by uncontrolled clonal.
Analytic Phase of Laboratory Testing
ICCS e-Newsletter CSI Spring 2014 Hong Lin, PhD and Cristina McLaughlin, MD APP-Unipath Denver, Colorado.
A Hematology Case Study about Leukemia by Sarah Wycoff
LEUKEMIA—HEMATOLOGY {S1}
ECSI case Fall 2014 Andrea M. Sheehan, MD Associate Professor of Pathology & Immunology Baylor College of Medicine.
Leukemias.
Anemia Lab MHD I November 3, Case 1 A CBC is ordered on a 32-year old healthy man as part of a life-insurance policy evaluation.
MT 417 – Clinical Hematology II Manual/Special Tests Unit
Acute Leukaemia Dr. Soheir Adam, MRCPath Assistant Professor Department of Haematology, KAUH.
Identification and Diagnosis of the Acute Leukemias
Introduction to Flow Cytometry
ICCS e-newsletter CSI Summer 2011 Jeannine T. Holden, MD Emory University School of Medicine Atlanta, GA.
NYU Medicine Grand Rounds Clinical Vignette Maryann Kwa, MD PGY-2 January 12, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.
History 2: 70 year old female
Clinical Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia With the t(4;ll) (q21;q23) By Ching-Hon Pui, Lawrence S. Frankel,
ICCS e-Newsletter CSI Spring 2015 Prashanti Reddy, M.D., M.S. Senior Staff Hematopathologist Genoptix, Inc., a Novartis company.
HEMATOLOGY the branch of medicine devoted to the study of blood, blood-producing tissues, and diseases of the blood.
Acute Myeloid Leukemias Diagnosis in The Light of WHO Revisions And Correlation With Risk Adaptive Management ; Case Discussions Dr. Rania Medhat Seliem.
MOLECULAR GENETICS and LEUKEMIA Clive S. Zent M.D. Division of Hematology/Oncology.
Characteristics Useful for the Diagnosis and Classification of Non-Lymphoid Neoplasms Gross Pathology Counts and Cytology Blood Bone Marrow Lineage Assessment.
ICCS e-Newsletter CSI Fall 2010 David D. Grier, M.D. Department of Pathology. Wake Forest University.
4th Year Medical Student KAU
Red blood cell disorders / Anemia laboratory
MLAB 1415: Hematology Keri Brophy-Martinez
Acute Leukemia Kristine Krafts, M.D..
ICCS e-Newsletter CSI Hamid Zia, MD Andrew Chu, MD Franklin Fuda, DO Department of Pathology University of Texas Southwestern Medical Center Dallas, Texas.
Case 297 Guilin Tang and Sa A. Wang Department of Hematopathology UT MD Anderson Cancer Center.
CASE 205 Denyo Adjoa Zakhia, MD Kristin Hunt Karner, MD Henry Ford Hospital, Detroit, MI.
Minimal Residual Disease(MRD) detections by Flow Cytometry in Acute Leukemia 혈액학파트 안 미 숙.
Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.
LEUKEMIA Dr. Omar Alshaer. Acute Leukemia.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
Hematology There are four lectures: 1.Acute leukemias (2 hours). 2.Chronic leukemias (2 hours).
Society for Hematopathology/European Association for Haematopathology 2013 Case Number 208 Erika Moore, MD; Darshan Roy, MD; Patti Cohen, MD; Adam Bagg,
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
SH/EAHP 2013 Workshop Case 285 Sara-Eloína Cuadra-Acree, MD,* Kiran Qidwai, MD,* Brit Shackley, MD,** & Imran N. Siddiqi, MD, PhD* * University of Southern.
Case 316 Ryan Johnson, MD; Athena Cherry, PhD; Dita Gratzinger, MD, PhD Stanford University Medical Center SH-EAHP October 24, 2013.
CASE 411 Jose Gonzalez-Berjon, MD & Tariq Muzzafar, MD UT M.D. Anderson Cancer Center.
ICCS e-Newsletter CSI Fall 2015 Hywyn R. O. Churchill, MD PhD Division of Hematopathology.
eCSI case Weijie Li, MD Department of Pathology & Laboratory Medicine
Acute Leukemia Kristine Krafts, M.D..
CASE OF THE MONTH Dr Narender Tejwani Consultant ( Hematopathologist)
Adam J. Wood, D.O. Rhett P. Ketterling, M.D. April E. Chiu, M.D.
Case Study Interpretation
eCSI case 2 – November 2016 Jyotinder Nain Punia, MD
CASE SUBMISSION 2016 EAHP BM Workshop
CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES
ICCS e-Newsletter CSI Yao Schmidt, MD Department of Pathology
Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.
Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;
CHRONIC MYELOID LEUKEMIA (CML)
Early T-Cell Precursor ALL in 5 Year Old Female
ICCS e-newsletter CSI Sean R McMaster and George Deeb
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification by Estella.
Flow cytometric immunophenotyping for hematologic neoplasms
University of Vermont Medical Center
by Michele Paessler, and John Choi
IMMUNOPHENOTYPING LEUKEMIAS AND LYMPHOMAS
LEUKEMIA CASE STUDY 2.
Diagnostic Hematology
Donor Cell Leukemia in Umbilical Cord Blood Transplant Patients
ICCS Case of the Quarter
A presentation By Abedelaziz Taha Hammash supervisor \ Mr
Case study.
Leukemia case (18).
Neoplastic disorder.
Presentation transcript:

ICCS e-Newsletter CSI Winter 2013 Jacqueline Emmons, MD Department of Pathology University of Texas Southwestern Medical Center Dallas, Texas

History 11 month old female with a history of fever and failure to thrive On physical exam, the child was pale and lethargic.

CBC Data Normal Ranges WBC: 67 K/mm3 6 -- 17.5 K/mm3 RBC: 3.23 M/mm3 Hgb: 9.3 g/dL 11.1 – 14.2 g/dL Hct: 26% 30 – 42% MCV: 80.5 fl 70.0 – 84.0 fl MCHC: 35.8 g/dL 32.0 – 36.0 g/dL RDW: 14.1% 11.5 – 15.0% Plts: 62 K/mm3 150 – 600 K/mm3 A manual differential of the peripheral blood revealed 69% blasts.

A peripheral blood sample was received in the flow cytometry lab with the indication to “rule out acute leukemia.” Selected tubes from the diagnostic analysis are included in this case study for review.

A four color analysis was performed using a BD FACScalibur™ flow cytometer. An ungated, cluster analysis was performed with BD Paint-a-Gate™ software. Files are in FCS2.0 format. Tubes with the following antibody combinations are included for review. Tube FITC PE PerCP APC 1 CD10 CD22 CD20 CD34 2 CD14 CD11b CD19 3 CD45 CD11c 4 CD15 CD33 5 CD36 CD64 6 CD2 CD117 7 (intracellular) MPO CD79a

TUBE 1 Upon opening the file, it is apparent that there are a large number of CD34(+) events. After using CD34 to isolate the cells of interest (painted in red), the forward versus side scatter plot can be used to further define or “clean up” the population. Here, all events outside of the “blast gate” are highlighted in black and will be excluded. granulocytes doublets debris

TUBE 1 The CD34(+) blasts (red) are negative for CD20 and CD10 and are partial dim positive for CD22.

TUBE 2 As anti-CD34 is included in tube 2 as well, the blasts can be isolated and analyzed in a similar fashion to tube 1. In addition, other cell types can also be studied in this tube. To look for any CD34(-) monocytic cells, CD14 can be used to gate. The population can then be better defined using the forward versus side scatter and CD34. Exclusion of debris, lymphocytes, granulocytes, and doublets Exclusion of CD34(+)events

TUBE 2 Granulocytes painted green on forward versus side scatter eosinophils Neutrophilic elements Clean up with CD34(+)

TUBE 2 Small lymphocytes can be isolated by first painting on the forward versus side scatter. Some of the blasts are small and overlap with the lymphocyte gate in this plot. The CD34 can be used to exclude blasts. Then, CD14 can be used to exclude monocytes.

TUBE 2 A complete analysis of tube 2 with all cell populations analyzed would look like this: Color Key: Red: Blasts Light blue: Lymphocytes Dark blue: Monocytes Green: Granulocytes

TUBE 2 The blasts are CD19(partial +) and CD11b(partial +). A few of the blasts appear to express CD14.

Tubes 3 – 7 can all be analyzed in a similar manner to tubes 1 and 2. The immunophenotype of the blasts is as follows: CD34(+) CD2(-) CD10(-) CD11b(partial +) CD11c(partial +) CD14(few cells +) CD15(partial +) CD19(partial +) CD20(-) CD22(partial dim +) CD33(variably +) CD45(moderately +) CD64(partial +) Cytoplasmic CD79a(partial +) CD117(few cells +) Cytoplasmic MPO(-)

The blasts express markers of both myeloid and B-lymphoid differentiation. In addition to nonspecific myeloid markers such as CD15 and CD33, the blasts express markers suggesting monocytic differentiation (CD11c, dual expression of CD64 and CD36, a few cells positive for CD14) B-lymphoid markers include partial strong expression of CD19, partial expression of CD22, and partial expression of CD79a

Blasts in the peripheral blood smear. An NSE cytochemical stain supports monocytic differentiation (inset)

Evidence of MLL gene rearrangement by FISH Split MLL gene Intact MLL gene

Diagnosis: Mixed phenotype acute leukemia, B/myeloid with MLL gene rearranged

Mixed phenotype acute leukemia (MPAL) MPALs express markers of one or more lineages to a significant degree MPALs may be: Bilineal: two separate blast populations each of a different lineage Biphenotypic: one blast population expressing markers of two different lineages Rare cases showing trilineage differentiation have been described Specific cytogenetic abnormalities may be associated with MPAL t(9;22)(q34;q11.2);BCR-ABL1 t(v;11q23);MLL rearranged Flow cytometry is integral in the diagnosis of MPAL

Requirements for assigning more than one lineage to a blast population (2008 WHO Classification) Myeloid lineage: Myeloperoxidase (MPO) by flow cytometry, IHC, or cytochemistry OR Evidence of monocytic differentiation (2 or more of the following: NSE, CD11c, CD14, CD64, lysozyme) B lineage: Strong CD19 with strong expression of at least one of the following: CD79a, cCD22, CD10 OR Weak CD19 with strong expression of at least 2 of the following: CD79a, cCD22, CD10 T lineage: cCD3, preferably by flow cytometry (IHC may detect CD3 zeta chain which is not T cell specific) OR sCD3 (rare)

MPAL with MLL gene rearranged The case presented is characteristic for an MPAL with MLL gene rearrangement MPAL with MLL rearranged is more common in the pediatric population, particularly in infants Patients typically present with a high white blood cell count The leukemia usually demonstrates evidence of both monocytic and B-lymphoid differentiation Commonly, the leukemic blasts show two different populations morphologically – a population of monoblasts and a population of lymphoblasts Some cases may present with one population of blasts with no clear distinguishing features by morphology CD10 is usually negative CD22 and CD79a are often weak This type of acute leukemia is associated with a poor prognosis.

Mixed Lineage Leukemia gene (MLL) on chromosome 11q23 MLL is not only implicated in MPAL in infants Rearrangements of the MLL gene occur in acute leukemias in patients of all ages and often in therapy-related hematopoietic neoplasms after treatment with topoisomerase II inhibitors MLL rearrangements can be seen in ALL, AML, and MPAL Account for >70% of infant leukemias Large and diverse group of translocation partners Over 50 translocation partners have been characterized

Mixed Lineage Leukemia gene (MLL) on chromosome 11q23 AML with MLL rearrangement usually shows evidence of monocytic differentiation BLL with MLL rearrangement tends to occur in infants presenting with a high white blood cell count and CNS involvement. The leukemic cells are characteristically CD10(-).

References Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012;7:283-301. Matutes E., Pickl WF, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011 Mar 17;117(11):3163-71. Sam TN, Kersey JH, Linabery AM, et al. MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study. Pediatr Blood Cancer. 2012 Jun;58(6):836-9